Circassia Pharmaceuticals (CSSPF) Stock Statistics & Valuation Metrics

Circassia Pharmaceuticals has a market cap or net worth of £348.53M. The enterprise value is $235.23M.

Circassia Pharmaceuticals has ― shares outstanding. The number of shares has decreased by -2.65% in one year.

Circassia Pharmaceuticals’s return on equity (ROE) is 0.13 and return on invested capital (ROIC) is 12.55%.

The current PE Ratio of Circassia Pharmaceuticals is 2.63K. Circassia Pharmaceuticals’s PEG ratio is -78.32.

In the last 12 months, Circassia Pharmaceuticals had revenue of 36.80M and earned 10.70M in profits. Earnings per share was 0.02.

In the last 12 months, operating cash flow was 15.80M and capital expenditures -100.00K, giving a free cash flow of 15.70M billion.

Circassia Pharmaceuticals pays an annual dividend of $0.013, resulting in a dividend yield of 1.52%

Circassia Pharmaceuticals upcoming earnings date is Sep 11, 2025, TBA Not Confirmed.

Circassia Pharmaceuticals as a current ratio of 4.65, with Debt / Equity ratio of 1.10%

In the past 12 months, Circassia Pharmaceuticals has paid -5.40M in taxes.

Circassia Pharmaceuticals EV to EBITDA ratio is 3.23K, with an EV/FCF ratio of 2.49K.

Circassia Pharmaceuticals has £21.50M in cash and marketable securities with £1.10M in debt, giving a net cash position of -£20.60M billion.

Gross margin is 71.79%, with operating margin of 12.50%, and net profit margin of 29.08%.

The average price target for Circassia Pharmaceuticals is £1.14, which is 11.43% higher than the current price. The consensus rating is Strong Buy